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Chronic inflammation is associated with both benign conditions and cancer. Likewise, 
inflammatory cells are quite common in benign prostatic hyperplasia (BPH) and prostatic 
tissue harboring cancer. Triggers that activate inflammatory pathways in the prostate 
remain a subject of argument and are likely to be multifactorial, some of these being 
bacterial antigens, different chemical irritations, and metabolic disorders. Acute and 
chronic inflammation in prostate leads to accumulation of immunocompetent cells, 
mainly T  lymphocytes and macrophages, but also neutrophils, eosinophils, and mast 
cells, depending on the type of offending agent. Inflammatory processes activate hyper-
proliferative programs resulting in nodules seen in BPH, but are also important in creating 
suitable microenvironment for cancer growth and progression. Inflammatory cells have 
mostly been shown to have a protumoral effect such as tumor-associated macrophages, 
but some cell types such as mast cells have antitumoral effects. This review outlines the 
recent findings and theories supporting the role of inflammatory responses as drivers of 
both benign and malignant epithelial processes in the prostate gland.
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inTRODUCTiOn
The vast majority (90%) of all cancers are linked to somatic mutations and environmental factors. 
It is assumed that chronic inflammation, including infections and autoimmune diseases, as well as 
inflammatory conditions of uncertain origin are important in creating suitable microenvironment 
for cancer growth and progression. Long-lasting inflammation is also present in many benign condi-
tions but without apparent proof of cancer growth (1–5).
Several multi-center studies demonstrated that the presence of various polymorphisms in genes 
coding for interleukins (ILs) such as IL-1, IL-6, and/or IL-8 is strongly associated with increased risk 
of cancer development. However, the role of inflammatory signals in tumor initiation is difficult to 
define due to multitude of molecules and mechanisms involved and also owing to lack of appropriate 
experimental models (1–4).
Benign prostatic hyperplasia (BPH) has been shown to be associated with inflammatory environ-
ment, and recent studies suggest there may be inflammation-related prostate cancer growth as well. 
In this review, we will display short reflection on such studies.
FigURe 2 | Prostate cancer. Scattered mononuclears can be seen 
between the neoplastic prostatic glands. A collection of lymphocytes, plasma 
cells, and macrophages can be seen at the periphery (HE, ×200).
FigURe 1 | Benign prostatic hyperplasia. Inflammatory cells, mostly 
mononuclears and sparse granulocytes can be seen in the stroma 
surrounding benign prostatic glands. There are also a few intraepithelial 
granulocytes (HE, ×200).
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BPH AnD inFLAMMATiOn
Benign prostatic hyperplasia is a chronic, slowly progressive dis-
ease, characterized by growth of epithelial and stromal cells from 
the transition zone and periurethral areas. It is almost physiologi-
cal process, present in most men after 50 years and some amount 
of chronic inflammation is inevitably present (Figure 1) (6–8). 
It is the most common cause of lower urinary tract symptoms in 
men, causing a deterioration in urinary function and increased 
risk of urinary tract infection, as well as increased risk of acute 
urinary retention (9).
Benign prostatic hyperplasia is caused by changes in hormone 
balance and consequently in cell growth, but molecular pathways 
leading to this condition are still largely unknown. Inflammatory 
component is believed to have an important role while presence 
and degree of inflammation corresponds to prostate volume 
and weight (6, 10). The origin of inflammation in the prostate 
remains a subject of argument and is likely to be multifactorial. 
It represents a chronic process of wound healing, which activates 
hyperproliferative programs resulting in BPH nodules (6, 10).
Acute and chronic inflammation leads to accumulation of 
immunocompetent cells in the prostate, mainly T lymphocytes and 
macrophages. However, many other cell types may be observed, 
including neutrophils, eosinophils, and mast cells, depending on 
the type of offending agent (11). Most of the lymphocyte popula-
tion around prostate glands are CD8+ T-lymphocytes while 
stroma mostly contains clusters of B-lymphocytes enclosed with 
CD4+ T-lymphocytes (8). Not only lymphocytes but also stromal 
and epithelial cells have cytokine receptors on membrane surface, 
participating in the local immune response (11–13).
Inflammatory pathways are triggered by viral or bacterial anti-
gens, as well as different chemical irritations and metabolic disor-
ders. Both prostate epithelial and stromal cells and inflammatory 
cells produce cytokines (CCL-5, CCL-2), ILs (IL-1α, IL-1β, IL-6, 
IL-18), and hypoxia-inducible factor-1α (HIF-1α), creating local 
inflammatory microenvironment (13–15). Abundant lymphoid 
infiltrates with a massive increase in CD4+ T-lymphocytes, as 
well as macrophages and mast cells, are noted in chronic prostate 
inflammation (9). These cells participate in pathological changes 
characteristic for both BPH and prostate carcinoma. There are 
several studies demonstrating that ILs, which have a pro-inflam-
matory role, may lead to initiation and progression of BPH (11, 
14–18). McDowell and associates showed how inflammatory cells 
can be attracted to the prostate tissue microenvironment and can 
selectively promote the proliferation of prostate epithelial cells 
(19). Further studies have confirmed IL-17 to be the initiator of 
BPH progression via activation of the nuclear-factor-kappa-B 
(NF-κB) pathway, which leads to secretion of other pro-inflam-
matory cytokines, such as IL-1, IL-6, and IL-8. Steiner et al. (20) 
demonstrated that healthy prostates do not express IL-17, whereas 
prostates with inflammation and BPH do. Wang et al. (21) also 
found cyclooxygenase 2 (COX-2) expressed in macrophages and 
epithelial prostate cells within significant inflammation. Under 
certain conditions, if high level of T-lymphocytes is reached, sur-
rounding cells are killed by CD8+ cytotoxic T cells and prostatic 
tissue is replaced by fibromuscular nodules (9, 12). Local hypoxia 
and inflammation also promote fibroblast to myofibroblast 
transformation, which leads to extracellular changes forming 
suitable microenvironment for continuous inflammation (9, 13, 
22). Inflammation is also continuously stimulated by androgens 
and changes within metabolic syndromes, but exact pathways are 
still mostly unknown (12, 23, 24).
PROSTATe CAnCeR AnD inFLAMMATiOn
Prostate cancer is one of well-known malignant diseases with 
multifactorial causes and acquired genetic and epigenetic changes 
(Figure 2). Chronic inflammatory microenvironment is consid-
ered to have a contribution in the development of prostate cancer. 
Two molecular and cellular pathways link inflammation and 
TABLe 1 | Roles of inflammatory cells and mediators in prostate cancer.
Cell type Chemokine Pathway Anti/protumoral development
Tregs, NKT IL-2 IL-2-dependent 
mechanisms
 – Chemokine secretion in stimulation of tumor progression
Cell-contact dependent 
mechanisms
 – Suppression of proliferation, cytokine release, and cytotoxic activity of NKT cells
Tumor-Tumor-associated 
macrophages
IFN-γ M1 pathway  – Against tumor activity
IL-3, IL-4, IL-10, CCL17, 
CCL2, CSF-1, VEGF, COX-
2, PGE2
M2 pathway  – Tissue remodeling—tumor promotion toward M2
 – Angiogenesis
 – Cancer cell proliferation
TNF-α, IL-1, IL-6, VEGF NF-κB  – Activation of pro-inflammatory genes (COX-2, iNOS, TNF-α, IL-1, IL-6)
 – Activation of antiapoptotic genes (Bcl-2, Bcl-X)
 – Activation of proangiogenic molecules (VEGF)
CCM-2, MIC-1  – Tumor-promoting macrophage infiltration in prostate cancer
 – Promotion of local invasion and metastases
STAT-3 Androgen 
receptor—CCL4-STAT3
 – Downregulation of p53/PTEN tumor suppressors
 – Promotion of epithelial-to-mesenchymal transition pathways
IL-1, TNF, IL-6, IL-18  – Microenvironmental niches for preserving tumor cells
Inflammasome Inflamm. regulators  – May be cancer specific
Neutrophils (high level) Neutrophil–lymphocyte 
ratio
 – Poor overall survival and recurrence-free survival
Mast cells (low 
intratumoral count)
 – Higher risk of prostate cancer recurrence
Tregs, regulatory T cells; NKT, natural killer T cells; IL, interleukin; IFN-γ, interferon γ; CCL, chemokines; CSF-1, macrophage colony-stimulating factor 1; VEGF, vascular endothelial 
growth factor; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2; NF-κB, transcriptional regulation family; CCM-2, monocyte chemoattractant protein 1; MIC-1, macrophage 
inhibitory cytokine; STAT-3, signal transducer and activator 3.
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cancer, intrinsic end extrinsic. In the intrinsic one, oncogenes are 
activated and pushed to the expression of inflammation-related 
programs. In the extrinsic pathway, inflammation itself is the pro-
moter of cancer development. In both scenarios, inflammatory 
microenvironment is present (Table  1). Transcription factors, 
such as TNF-α and β, Stat3, HIF-1, cytokines, and chemokines 
are main molecules that promote such state.
Different studies showed the association between specific 
immune cells and prostate cancer, especially CD3+, CD4+, and 
CD8+ cells in tissue obtained by prostatectomy or biopsy and 
found some of these cells to be pro-tumorigenic (25–27). For a 
detailed table summarizing the findings of the role of immune 
cells in prostate cancer, please see a review by Strasner and Karin 
(26). There are also studies demonstrating protective inflamma-
tory activity in prostate cancer, showing that subsets of T-cells 
may play an important role in immune reaction to prostate cancer 
(26, 28). Similar results were obtained on animal models (29). 
Regulatory T cells (Tregs) and NKT cells are two subpopulations 
of T lymphocytes that independently regulate innate and adap-
tive immunity. Activated NKT  cells can influence the function 
of Tregs through IL-2-dependent mechanisms. Tregs can also 
suppress proliferation, cytokine release, and cytotoxic activity of 
NKT  cells by cell-contact-dependent mechanisms. Tumor cells 
stimulate T cells and interact with the tumor-infiltrative innate 
immune cells secreting cytokines that are crucial for T-cell 
differentiation (11). Mrakovčić-Šutić et al. (11) showed that, in 
prostate cancer, number of Tregs is elevated and percentage of 
NKT cells is slightly diminished compared to patients with BPH 
(11). Although the exact mechanism is still unknown, increased 
infiltration of prostate tissue with T  regulatory cells seems to 
stimulate the tumor to secrete different chemokines that attract 
these cells in the prostate tissue where they may contribute to 
tumor progression.
It is believed that tumor-associated macrophages (TAMs) are 
one of the most important inflammatory cells due to their capa-
bility to promote anti- and protumor conditions. Macrophages 
and polymorphonuclears can polarize in response to different ILs 
and interferon and as such are important for tumor promotion 
(2, 3). Polarized cells can show anti and pro-tumoral response 
and in most studies inflammatory cells in tumor tissue showed 
protumoral polarization, which depends on pathways guided by 
different types of ILs.
In classical macrophage activation pathway (M1), macrophages 
are exposed to interferon-γ and react against tumor activity. 
Macrophages can also act through M2 activation pathway. In that 
case, they respond to IL-3 or IL-4 and promote tissue remodeling 
in a way of tumor promotion (2, 30). In most, but not all analyzed 
tumors, TAMs have an M2-like phenotype, which leads to the 
main question—which are the pathways leading to development 
of pro-tumoral inflammatory environment (31, 32)?
There are studies showing that extracellular matrix compo-
nents, IL-10, chemokines CCL17 and CCL2, and CSF-1 produced 
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by tumor cells drive macrophages toward M2 mode (2, 31, 32). 
Different pathways are shown to produce such changes in differ-
ent tumor types (32–34).
The infiltration of macrophages and immune suppressor cells 
was found to have a positive correlation to prostate cancer pro-
gression (27, 35, 36). There is some evidence that TAM count is 
important prognostic factor for clinical outcome and recurrence 
of prostate cancer (26, 37). TAMs are also related to increased 
production of mediators that promote angiogenesis [vascular 
endothelial growth factor, COX-2-derived prostaglandin E2], 
as well as cancer cell proliferation. NF-κB is important in these 
cellular alterations and is associated with insensitivity to growth 
inhibition, resistance to apoptotic signals, angiogenesis, tissue 
invasion and metastasis (38–40). It activates pro-inflammatory 
genes (COX-2, iNOS, TNF-α, IL-1, and IL-6) in tumor and tumor-
associated cells and surrounding tissue, as well as antiapoptotic 
(Bcl-2, Bcl-X) and proangiogenic molecules (vascular endothelial 
growth factor). Hypoxia appears to impact NF-κB signaling in 
TAMs, activating their pro-tumor orientation (41). Hypoxia and 
inflammation are both characteristics of prostate tumor microen-
vironment so HIFs and NF-κB are the key regulators of response 
to those stresses. Androgen and estrogen receptors also interact 
with this signaling pathway (42).
Monocyte chemoattractant protein 1 (CCM-2) is also a 
chemokine playing a role in tumor-promoting macrophage 
infiltration in prostate cancer, as well as its polarization into 
M2 phenotype (33). Macrophage inhibitory cytokine (MIC-1) 
or prostate-derived factor was described as molecule that can 
inhibit the secretion of TNF-α by activated macrophages and 
reduce tumor destruction, thus influencing the microenviron-
ment in favor of prostate cancer growth. Increased MIC-1 
concentration was found in high-grade prostate intraepithelial 
neoplasia and high-grade prostate cancer compared to normal 
prostate epithelial cells (43, 44). It was also shown that MIC-1 
increases in serum with the progression of metastatic prostate 
cancer, in a similar way as prostate-specific antigen (PSA) (45, 
46). These results are confirmed on animal mice models where 
increased MIC-1 gene expression correlated with increased 
level of prostate infiltrating lymphocytes. In similar models, 
germ line gene deletion of MIC-1/GDF15 resulted in increased 
local tumor growth. In late tumor development, MIC-1 over-
expression showed promotion of local invasion and metastases 
(45, 47, 48).
Signal transducer and activator 3 (STAT-3) is also important 
due to its activation in malignant cells that stimulates proliferation, 
survival, and angiogenesis. STAT-3 activation in immune cells 
promotes differentiation and recruitment of TAMs, invasion, and 
tumor-promoting inflammation (49). It is a well-known driver 
of premalignant and malignant lesions in pancreatic cancer (50, 
51). Prostate cell lines models, which recapitulated an interaction 
between immortalized prostate epithelial cells (RWPE-1 cells) 
and macrophages have shown that infiltrating macrophages 
per se (without additional carcinogens) can induce tumorigenesis 
in prostate via the pathway androgen receptor-inflammatory 
cytokine CCL4-STAT3 activation with downregulation of p53/
PTEN tumor suppressors, and promotion of epithelial-to-
mesenchymal transition pathways (52, 53).
The receptor for advanced glycation end products (RAGE) 
has also been described as an important element that drives an 
inflammatory milieu and some clinical studies demonstrated its 
strong association with the malignant potential of various cancer 
types (54–59). Higher RAGE expression was found in prostate 
cell lines compared to normal prostate epithelial cells, with 
various pathways of RAGE activation being proposed (60). Zhao 
et  al. (61) investigated immunohistochemical RAGE expres-
sion, together with high-mobility group protein 1 (HMGB1) 
in 85 prostate cancer patient. Its high expression was related to 
advanced clinical stage as well as high PSA level, which suggest 
that the expression of RAGE and HMGB1 is associated with the 
progression and poor prognosis of prostate cancer (61).
Macrophages and some of their products (IL-1, TNF, IL-6, 
and IL-18) are also known to increase the likelihood of metas-
tasis while creating appropriate microenvironmental niches for 
preserving tumor cells (62, 63).
We should also mention the emerging class of a multimeric 
protein group called inflammasomes, which are considered to be 
important regulators of inflammation. The role of inflammasomes 
could be cancer-specific but additional studies are needed (27).
Some other cell types, as neutrophils and mast cells were also 
designated as part of inflammatory response in prostate cancer 
(26). Tang et  al. (64) performed a meta-analysis studying a 
predictive value of neutrophil–lymphocyte ratio (NLR) in overall 
survival, recurrence-free survival, and clinical features in prostate 
cancer patients (64). It included 9,418 patients from 18 studies. 
They showed that poor overall survival and recurrence-free sur-
vival were related to high pretreatment NLR. It also correlated 
to lymph node involvement. Localized cancer was not related to 
increased NLR (64).
Mast cells are present in inflammatory environment of the 
prostate cancer and can provide pro- and antitumoral activities 
(65). Hempel et al. (66) showed a protective role of intratumoral 
mastocytes connecting a low number of intratumoral mast cells 
with a higher risk of prostate cancer recurrence (66).
There are some studies that consider inflammation to be 
related to changes in the proliferative inflammatory atrophy as 
precursor of low- and high-grade prostatic intraepithelial neo-
plasia and cancer, but it is not likely that inflammation alone can 
run this pathway (67–70).
It is well known that inflammatory microenvironment is 
important in growth and progression of prostate tumor cells; 
macrophages and other immune cells show positive correlation 
to prostate cancer progression. It is also known that inflammation 
can have antitumoral effect so different inflammatory pathways 
and pro-inflammatory cytokines and chemokines are equally 
important to be included in screening of prostate cancer patients 
and in decision of therapy and prognosis.
Therapeutic possibilities include immunovaccines, immu-
nomodulators, monoclonal antibodies, and adoptive T-cell thera-
pies, meaning there are many ongoing trials targeting immune 
cells and their mediators in attempt to slow down prostate cancer 
progression. Currently investigated immunovacines include den-
dritic cell vaccine with a chimeric protein as a tumor-associated 
antigen; PSA antigen co-stimulatory molecules delivered in viral 
vectors; irradiated prostate cancer cell lines; adenovirus/PSA 
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vaccine in men with recurrent cancer after local therapy and with 
hormone refractory cancer; DNA-based vaccines and adenoviral 
vector-expressing Herpes virus thymidine kinase, which targets 
tumor cells and is followed by anti-herpes drug (71). Immune 
modulators used in studies include cytotoxic T-lymphocyte-
associated antigen 4 and CT-011 anti-programmed death recep-
tor-1 for advanced stages of prostate cancer. As adoptive cell 
therapy, T  cells genetically engineered to target cancer specific 
antigen NY-ESO-1 in combination with other therapy options is 
used (72, 73). Monoclonal antibody targeting CD20 as neoadju-
vant therapy is also under investigation (26, 74).
Some of these therapies are in the phase III trial and although 
targeted immune therapy is promising, it needs further assess-
ment and will probably be used in combination with other 
therapeutic agents and approaches.
COnCLUSiOn
Although the pathogenesis of BPH is not fully understood, most 
of the recent studies strongly suggest that the T-cell activity and 
associated autoimmune reaction induce epithelial and stromal 
cell proliferation. Further understanding of the inflammatory 
pathways will expand the knowledge of BPH pathogenesis and 
potentiate screening for patients presenting with BPH-related 
symptoms, as well as some novel biomarkers of prostatic inflam-
mation and treatment strategies.
Inflammatory cells are quite common in BPH and are seen 
in prostatic tissue harboring cancer. Recent evidence support 
theories that chronic inflammation and immune response might 
be common drivers for both diseases, at least in some cases. 
The exact mechanisms directing inflammatory pathways into 
pro-benign (BPH) or pro-malignant microenvironment are still 
unknown.
Nowadays, many concepts are aimed toward tumor microen-
vironment, such as tumor stroma molecules or inflammation/
immune cells, and are trying to find suitable biomarkers in this 
multitude of different possible targets. Therapeutic possibilities 
include immunovaccines, immunomodulators, monoclonal anti-
bodies, and adoptive T-cell therapies. Most probable treatment 
options will combine standard and novel therapeutic targets.
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